Effect of Bezafibrate or Pravastatin on Serum Lipid Levels and Albuminuria in NIDDM Patients

Nagai, Takashi; Tomizawa, Takashi; Nakajima, Katsuyuki; Mori, Masatomo

doi:10.5551/jat1994.7.91

Cited by 38 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also of interest to note that bezafi brate reduced the LDL-C level after 24 h (Table I), but not after 7 h. Furthermore, other plasma lipid levels were not signifi cantly changed indicating that bezafi brate has an acute lowering activity only on plasma triglycerides and LDL-C. This is concomitant with the mechanism of action of fi brates (Fujiwara et al, 1997;Yamada, 1997;Norioka et al, 2000;Nagai et al, 2000;Hikita et al, 2000) whose LDL-C-lowering activity is not strongly marked, but their triglycerides-decreasing effect is very spectacular especially by stimulation of gene expression of lipoprotein lipase leading to enhanced catabolism of VLDL, synthesis of fatty acids and reduced VLDL secretion.…”

Section: Discussionmentioning

confidence: 60%

Pharmacological Evaluation of Novel Indole-2-carboxamides As Potent Lipid-Lowering Agents in Triton-WR-1339-Induced Hyperlipidemic Rats

Al-Qirim

Shahwan

Shattat

et al. 2009

Zeitschrift Für Naturforschung C

View full text Add to dashboard Cite

The lipid-lowering effects of two novel antihyperlipidemic agents, BMI2C [N-(4-benzoylphenyl)-5-methoxy-1H-indole-2-carboxamide] and DDMI2C [N-(9,10-dihydro-9,10-dioxoanthracen-2-yl)-5-methoxy-1H-indole-2-carboxamide], were studied using hyperlipidemic rats as an experimental model; hyperlipidemia was developed by intraperitoneal injection of Triton WR-1339 (200 mg/kg body weight). At a dose of 15 mg/kg body weight, BMI2C and DDMI2C signifi cantly reduced elevated plasma triglyceride levels after 7 and 24 h. Furthermore, BMI2C and DDMI2C signifi cantly reduced elevated plasma total cholesterol levels after 24 h. Interestingly, high-density lipoprotein-cholesterol levels were signifi cantly increased in all treated groups. These fi ndings indicate that the two studied novel compounds have a promising potential in the treatment of hyperlipidemia and atherosclerosis. Key words: BMI2C [N-(4-Benzoylphenyl)-5-methoxy-1H-indole-2-carboxamide], DDMI2C[N-(9,10-Dihydro-9,10-dioxoanthracen-2-yl)-5-methoxy-1H-indole-2-carboxa mide], Antihyperlipidemic Activity

show abstract

Section: Discussionmentioning

confidence: 60%

Pharmacological Evaluation of Novel Indole-2-carboxamides As Potent Lipid-Lowering Agents in Triton-WR-1339-Induced Hyperlipidemic Rats

Al-Qirim

Shahwan

Shattat

et al. 2009

Zeitschrift Für Naturforschung C

View full text Add to dashboard Cite

show abstract

“…The evidence presented above provides a strong rationale for the use of pharmacological inhibitors of NADPH oxidase to combat oxidative stress and its associated vascular pathologies. The current research interest is to treat diabetic nephropathy by use of a fibrates class of interventions, such as fenofibrate, bezafibrate and gemfibrozil, well-known hypolipidemic agents [80][81][82] . Recently, in our laboratory we have shown that treatment with fenofibrate and concurrent administration of benfotiamine, a transketolase activator, prevented the development of diabetic nephropathy.…”

Section: Pharmacological Interventions To Treat Diabetic Smokers Withmentioning

confidence: 99%

Smoking in diabetic nephropathy: sparks in the fuel tank?

Chakkarwar¹

2012

WJD

View full text Add to dashboard Cite

Diabetic nephropathy is associated with high morbidity and mortality and the prevalence of this disease is continuously increasing worldwide. Long-term diabetes increases the likelihood of developing secondary complications like nephropathy, the most common cause of end stage renal disease. Usually, other factors like hypertension, alcoholism and smoking also partly contribute to the progression of diabetic nephropathy. Among this, cigarette smoking in diabetes has been repeatedly confirmed as an independent risk factor for the onset and progression of diabetic nephropathy. Various studies suggest that smoking is a major fuel in the development of high oxidative stress and subsequently hyperlipidemia, accumulation of advanced glycation end products, activation of the renin angiotensin system and Rho-kinase, which are observed to play a pathogenic role in the progression of diabetic nephropathy. Furthermore, cigarette smoking in diabetic patients with vascular complications produces a variety of pathological changes in the kidney, such as thickening of the glomerular basement membrane and mesangial expansion with progression in glomerulosclerosis and interstitial fibrosis, which ultimately results in end stage renal failure. Strong associations are consistently found between chronic cigarette smoking and diabetic microvascular complications. A diverse group of studies unveil potential mechanisms that may explain the role of cigarette smoking in the progression of diabetic nephropathy. Tremendous efforts are being made to control smoking mediated progression of diabetic nephropathy, but no promising therapy is yet available. The present review critically discusses the possible detrimental role of chronic cigarette smoking in the progression of diabetic nephropathy and various possible pharmacological interventions to attenuate the exacerbation of diabetic nephropathy.

show abstract

“…6,7 Moreover, it has been shown that high levels of RLP-C are an independent risk factor for CV events in patients with type 2 diabetes mellitus. 12 We and others have shown that treatment with fibrates, including bezafibrate or gemfibrozil, effectively reduces RLP-C levels, 8,13, 14 and treatment with statins has also resulted in a significant reduction in RLP-C levels. 14, 15 However, those previous studies had small numbers of patients.…”

mentioning

confidence: 99%

Comparative Study of Bezafibrate and Pravastatin in Patients With Coronary Artery Disease and High Levels of Remnant Lipoprotein

Sano

Nakamura

Hirano

et al. 2010

Circ J

View full text Add to dashboard Cite

Background: Remnant lipoproteinemia is a strong risk factor for cardiovascular (CV) diseases. This study examined which of 2 common lipid-lowering drugs (fibrates and statins) is more effective in patients with remnant lipoproteinemia and if lowering remnant lipoprotein levels can reduce CV risk. Methods and Results:Remnant lipoprotein levels were measured by an immunoseparation method (remnantlike lipoprotein particles cholesterol: RLP-C) in 274 patients with coronary artery disease and high RLP-C levels (≥5.0 mg/dl). They were randomly assigned to receive bezafibrate (200-400 mg/day) or pravastatin (10-20 mg/day), and were prospectively followed-up for 1 year or until the occurrence of CV events. Complete follow-up data were obtained in 180 patients. RLP-C levels at 1 year of treatment were reduced more by bezafibrate than pravastatin (−37% and −25% from baseline, respectively). During follow-up, bezafibrate-treated patients had 3 CV events, compared with 12 events in pravastatin-treated patients (P<0.01). In multivariate logistic regression analysis, a decrease in RLP-C level was significantly associated with a reduction in CV events after adjustment for treatment group and changes in levels of other lipids. Conclusions:Bezafibrate therapy decreased RLP-C levels to a greater extent than pravastatin and a decrease in RLP-C level may be associated with a reduction in CV events in patients with high RLP-C levels. Effects of Fibrate and Statin on RLP-C Methods Study PatientsFrom 2003 December to 2005 March, 274 patients with CAD and high levels of RLP-C (≥5.0 mg/dl) at 17 hospitals (Appendix 1) were enrolled in this study. All patients met the following inclusion criteria: (1) total cholesterol (TC) level in fasting serum ≥180 mg/dl but <260 mg/dl; (2) TG level in fasting serum ≥150 mg/dl but <400 mg/dl; (3) presence of CAD based on angiographic evidence of organic diameter stenosis >50% of at least 1 major coronary artery, but patients were included if they had had a significant stenosis previously, which had been reduced to ≤50% after coronary revascularization; and (4) age 35-75 years. If lipid-lowering drugs were being administered at the time of enrollment, RLP-C, TC, high-density lipoprotein-cholesterol (HDL-C) and TG levels were measured after a wash-out period of more than 4 weeks. The exclusion criteria were: (1) acute coronary syndrome within 10 days prior to enrollment; (2) congestive heart failure (New York Heart Association class III or greater);

show abstract

Effect of Bezafibrate or Pravastatin on Serum Lipid Levels and Albuminuria in NIDDM Patients

Cited by 38 publications

References 17 publications

Pharmacological Evaluation of Novel Indole-2-carboxamides As Potent Lipid-Lowering Agents in Triton-WR-1339-Induced Hyperlipidemic Rats

Pharmacological Evaluation of Novel Indole-2-carboxamides As Potent Lipid-Lowering Agents in Triton-WR-1339-Induced Hyperlipidemic Rats

Smoking in diabetic nephropathy: sparks in the fuel tank?

Comparative Study of Bezafibrate and Pravastatin in Patients With Coronary Artery Disease and High Levels of Remnant Lipoprotein

Contact Info

Product

Resources

About